| P/E (FY) | — | Sales (TTM) | $2.0M |
| Earnings (TTM) | -$173.7M | ROE | −38.38% |
| Net Margin | −7973.33% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. Its lead candidate claseprubart is a monoclonal antibody with extended half-life and high selectivity for the active C1s complement protein, and DNTH212 is a bifunctional fusion protein that targets BDCA2 to reduce Type 1 interferon production while inhibiting BAFF/APRIL to suppress B cell function. The company is headquartered in New York.
| Market Cap | $5.55B | Trading Days | 716 |
| 52W High | 107.99 |
| 52W Low | 18.08 |
| % Off High | −5.91% |
| YTD | 146.57% | 1Y | 356.06% |
| Since incept. (ann.) | 116.71% |
License 100%
| Ann. Volatility (1Y) | 66.44% | Ann. Volatility (3Y) | 76.98% |
| Sharpe (1Y) | 2.66 | Sharpe (3Y) | 1.39 |
| Max Drawdown (1Y) | −20.16% | Max Drawdown (3Y) | −53.48% |
| Beta (3Y, vs SPY) | 0.07 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ERAS | Erasca, Inc. | $5.65B | — |
| ORKA | Oruka Therapeutics, Inc. | $5.46B | — |
| AMRN | AMARIN CORP PLC\UK | $5.31B | — |
| TVTX | Travere Therapeutics, Inc. | $5.20B | — |
| LGND | LIGAND PHARMACEUTICALS INC | $5.94B | 48.3 |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.98B | 85.3 |
| INDV | Indivior Pharmaceuticals, Inc. | $5.00B | 25.0 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.27B | 105.9 |
| XENE | Xenon Pharmaceuticals Inc. | $6.28B | — |
| COGT | Cogent Biosciences, Inc. | $6.48B | — |
| MANE | Veradermics, Inc | $4.66B |
| PTCT | PTC THERAPEUTICS, INC. | $6.66B | 9.7 |
